Design and optimization of novel Tetrahydro-β-carboline-based HDAC inhibitors with potent activities against tumor cell growth and metastasis

被引：0

作者：

Fan, Shule ^{[1
]}

Wan, Zeyi ^{[1
]}

Qu, Yuhua ^{[1
]}

Lu, Wenxia ^{[1
]}

Li, Xiangzhi ^{[1
]}

Yang, Feifei ^{[1
]}

Zhang, Hua ^{[1
]}

机构：

[1] Univ Jinan, Sch Biol Sci & Technol, Jinan 250022, Shandong Provin, Peoples R China

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2024年 / 114卷

基金：

中国国家自然科学基金;

关键词：

Tetrahydro-beta-carboline; Hydroxamate; HDAC inhibitors; Antitumor;

D O I：

10.1016/j.bmcl.2024.129986

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Histone deacetylases (HDACs) are validated drug targets for various therapeutic applications. A series of Tetrahydro-beta-carboline-based hydroxamate derivatives, designed as HDAC inhibitors (HDACis), were synthesized. Compound 11g exhibited strong inhibitory activity against HDAC1 and the A549 cancer cell line. Additionally, this compound increased the levels of acetylated histone H3 and H4. Notably, 11g effectively arrested A549 cells in the G2/M phase and also increased ROS production and DNA damage, thereby inducing apoptosis. Further molecular docking experiments illustrated the potential interactions between compound 11g and HDAC1. These findings suggested that the novel Tetrahydro-beta-carboline-based HDACis could serve as a promising framework for further optimization as anticancer agents.

引用

页数：9

共 50 条

[41] Structure-based design and optimization lead to the identification of novel dihydrothiopyrano[3,2-d] pyrimidine derivatives as potent HIV-1 inhibitors against drug-resistant variants
Zhao Wang
Heng Zhang
Zhen Gao
Zihao Sang
Erik De Clercq
Christophe Pannecouque
Dongwei Kang
Peng Zhan
Xinyong Liu
Acta Pharmaceutica Sinica B, 2024, 14 (03) : 1257 - 1282
[42] Design and Optimization of Novel Benzimidazole- and Imidazo[4,5-b]pyridine-Based ATM Kinase Inhibitors with Subnanomolar Activities
Dimitrov, Teodor
Moschopoulou, Athina Anastasia
Seidel, Lennart
Kronenberger, Thales
Kudolo, Mark
Poso, Antti
Geibel, Christian
Woelffing, Pascal
Dauch, Daniel
Zender, Lars
Schollmeyer, Dieter
Bajorath, Juergen
Forster, Michael
Laufer, Stefan
JOURNAL OF MEDICINAL CHEMISTRY, 2023, 66 (11) : 7304 - 7330
[43] Structure-based design and synthesis of imidazo[1,2-a]pyridine derivatives as novel and potent Nek2 inhibitors with in vitro and in vivo antitumor activities
Xi, Jian-Bei
Fang, Yan-Fen
Frett, Brendan
Zhu, Meng-Li
Zhu, Tong
Kong, Yan-Nan
Guan, Feng-Jie
Zhao, Yun
Zhang, Xiong-Wen
Li, Hong-Yu
Ma, Ming-Liang
Hu, Wenhao
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2017, 126 : 1083 - 1106
[44] Monoclonal Antibody against Cell Surface GRP78 as a Novel Agent in Suppressing PI3K/AKT Signaling, Tumor Growth, and Metastasis
Liu, Ren
Li, Xiuqing
Gao, Wenming
Zhou, Yue
Wey, Shiuan
Mitra, Satyajit K.
Krasnoperov, Valery
Dong, Dezheng
Liu, Shuanglong
Li, Dan
Zhu, Genyuan
Louie, Stan
Conti, Peter S.
Li, Zibo
Lee, Amy S.
Gill, Parkash S.
CLINICAL CANCER RESEARCH, 2013, 19 (24) : 6802 - 6811
[45] Novel potent azetidine-based compounds irreversibly inhibit Stat3 activation and induce antitumor response against human breast tumor growth in vivo
Yue, Peibin
Zhu, Yinsong
Brotherton-Pleiss, Christine
Fu, Wenzhen
Verma, Nagendra
Chen, Jasmine
Nakamura, Kayo
Chen, Weiliang
Chen, Yue
Alonso-Valenteen, Felix
Mikhael, Simoun
Medina-Kauwe, Lali
Kershaw, Kathleen M.
Celeridad, Maria
Pan, Songqin
Limpert, Allison S.
Sheffler, Douglas J.
Shiao, Stephen L.
Tius, Marcus A.
Lopez-Tapia, Francisco
Turkson, James
CANCER LETTERS, 2022, 534
[46] Structure-Based Design and Optimization Lead to the Identification of a Novel Potent sEH Inhibitor with PPARγ Partial Agonist Activity against Inflammatory and Metabolic-Related Diseases
Cao, Ruolin
Zhang, Maoying
Qi, Minggang
Zhang, Zhen
Morisseau, Christophe
Zhou, Chunwei
Sun, Tianqi
Zhuang, Junning
Chen, Lu
Xu, Cheng
Liu, Zhongbo
Hammock, Bruce D.
Chen, Guoliang
JOURNAL OF MEDICINAL CHEMISTRY, 2025,
[47] Identification of galiellalactone-based novel STAT3-selective inhibitors with cytotoxic activities against triple-negative breast cancer cell lines
Kim, Hyun Su
Kim, Taewoo
Ko, Hyejin
Lee, Jeeyeon
Kim, Yeong Shik
Suh, Young-Ger
BIOORGANIC & MEDICINAL CHEMISTRY, 2017, 25 (19) : 5032 - 5040
[48] Structure-based design, synthesis, and biological characterization of indolylarylsulfone derivatives as novel human immunodeficiency virus type 1 inhibitors with potent antiviral activities and favorable drug-like profiles
Wang, Zhao
Wang, Wenbo
Gao, Zhen
Gao, Huizhan
Clercq, Erik De
Pannecouque, Christophe
Chen, Chin-Ho
Kang, Dongwei
Zhan, Peng
Liu, Xinyong
JOURNAL OF MEDICAL VIROLOGY, 2024, 96 (08)
[49] Novel inhibitors of human histone deacetylases: Design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SARA-based non-hydroxamates
Suzuki, T
Nagano, Y
Kouketsu, A
Matsuura, A
Maruyama, S
Kurotaki, M
Nakagawa, H
Miyata, N
JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (04) : 1019 - 1032
[50] Structural optimization of diphenylpyrimidine scaffold as potent and selective epidermal growth factor receptor inhibitors against L858R/T790M resistance mutation in nonsmall cell lung cancer
Yi, Yuanyuan
Wang, Luhong
Zhao, Dan
Huang, Shanshan
Wang, Changyuan
Liu, Zhihao
Sun, Huijun
Liu, Kexin
Ma, Xiaodong
Li, Yanxia
CHEMICAL BIOLOGY & DRUG DESIGN, 2018, 92 (06) : 1988 - 1997

← 1 2 3 4 5 →